GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$39.21 USD
-1.03 (-2.56%)
Updated Oct 10, 2024 04:00 PM ET
Pre-Market: $38.87 -0.34 (-0.87%) 9:18 AM ET
3-Hold of 5 3
A Value C Growth F Momentum C VGM
Price, Consensus and EPS Surprise
GSK 39.21 -1.03(-2.56%)
Will GSK be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for GSK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GSK
GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy
Here's Why GSK (GSK) is a Strong Value Stock
GSK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
Biogen's Lupus Candidate Meets Key Goals in Phase III Study
CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease
Other News for GSK
World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice
Citi Keeps Their Buy Rating on GlaxoSmithKline (GSK)
GSK: The Worst Is Finally Over (Rating Upgrade)
GSK Leaders Invest in Share Reward Plan
Jim Cramer Likes Reddit Very Much, Calls Accenture A 'Great Buy'